Press release
2024-01-31
ImmuneBiotech Medical Sweden AB strengthens its Board of Directors by welcoming life science professional Sara Malcus as Chairman of the Board and Svante Hjertén as Board Member2023-05-11
ImmuneBiotech Medical Sweden AB announces the appointment of international microbiome expert Kristin Wannerberger to board of directors2021-01-20
ImmuneBiotech closes fully subscribed new share issue with funding from recognized investors and existing shareholders2020-09-22
ImmuneBiotech: Patent granted for GutMagnific® in the United States2020-06-10
ImmuneBiotech: starts clinical trial of GutMagnific® in ME/CFS in collaboration with Stora Sköndal ME clinic2019-10-16
ImmuneBiotech: market launch of first product GutMagnific2019-05-07
ImmuneBiotech: Winner of H2020 “SME Instrument” Phase 12019-01-24
ImmuneBiotech closes new share issue with funding from recognized international investors and business angels
News
January, 2024
ImmuneBiotech welcomes Sara Malcus as Chairman of the BoardJanuary, 2024
ImmuneBiotech’s End-Of-The-Year MessageNovember, 2023
ImmuneBiotech’s 10th anniversaryNovember, 2023
Our CEO Dr Shahram Lavasani is currently in the USA at the Microbiome Movement-Human Nutrition conference.November, 2023
Our CEO Shahram Lavasani was invited keynote speaker at Plovdiv University (Bulgaria) at the “Biotechnologies for Personalized Medicine” conference.November, 2023
Our 10-year anniversary is approaching!October, 2023
ImmuneBiotech featured in Dagens Nyheter (Sweden’s leading newspaper) October 16October, 2023
We´ll be talking at Malmö´s Rotary Club on the 9 th of October with a presentation on: Precision Probiotics: Your Path to Personalized Health
Press contact
For media inquiries, please write to info@immunebiotech.com
ImmuneBiotech AB
Scheelevägen 2, Medicon Village
223 81 Lund, Sweden
Phone: +46 46 25 25 50
GutMagnific Web Shop: www.GutMagnific.com
Follow us on LinkedIn for the latest updates and information.